Epstein Secrets

nts to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AR (10/22, Choe, Troise, Veiga) and the Wall Street Journal (10/22, Bartholomew, Eisen, Subscription Publication, 7.57M), and Bloomberg (10/22, Haigh, 4.73M) provide similar coverage. FDA Officially Approves Remdesivir As Cases

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

/22, Choe, Troise, Veiga) and the Wall Street Journal <https://www.wsj.com/articles/global-stock-markets-dow-update-10-22-2020-11603358278> (10/22, Bartholomew, Eisen, Subscription Publication, 7.57M), and Bloomberg <https://www.bloomberg.corninews/articles/2020-10-22/yields-up-on-stimulus-hopes-asia-stocks

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

nts to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AP (10/22, Choe, Troise, Veiga) and the Wall Street Journal (10/22, Bartholomew, Eisen, Subscription Publication, 7.57M), and Bloomberg (10/22, Haigh, 4.73M) provide similar coverage. FDA Officially Approves Remdesivir As Cases

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug